Bram Verstockt graduated medical school at the KU Leuven in 2013. During his medical training, he performed an internship at the Mater Dei Hospital, Malta. In 2015, he partially interrupted his residency in GI to start his PhD, which he successfully defended in 2019. During the first year of his PhD, he worked at the University of Cambridge, UK. In 2021 he graduated as gastroenterologist, and joined the IBD staff at the University Hospitals Leuven. In 2022 he was appointed assistant professor at KU Leuven. His translational research mainly focusses on the development of predictive and prognostic markers for a more personalised medicine in IBD, as well as on unravelling IBD disease heterogeneity (fibrosis, perianal disease, fatigue) through multi-omics and organoid approaches. Additionally, Bram does clinical research on monitoring tools (including intestinal ultrasound, IBUS curriculum 2021 with clinical/research stay in Lueneburg, Germany), real-life IBD data (including TDM) and is involved in various (inter)national studies. Bram is chair of the Belgian IBD biobank and the Scientific Committee of IBUS, and former chair of Y-ECCO. He is co-founder of the COLLIBRI proteomics consortium in IBD, board member in the ECCO guideline committee and the Scientific committee of BIRD. He is vice president of the European Microscopic Colitis group. He is associate editor of JCC. In 2025, he was awarded the UEG Rising Star and the ECCO Young Investigator Award.